RECCE ® 327 as a gel formulation (R327G) demonstrated a positive clinical response in the treatment of multiple antibiotic-resistant infections under the Therapeutic Goods Administration (TGA) Special ...

Over the last year, a good number of insiders have significantly increased their holdings in Recce Pharmaceuticals ...

Human Research Ethics Committee approval received for Phase II trial of R327 for acute bacterial skin and skin structure infections (ABSSSI), including diabetic foot and wound infections New site ...

A$5.0 million commitment received from Australian-based private investor A$10.8 million Entitlement Offer at the same offer price as the placement Funds to support Phase III Topical clinical trials in ...

To get a sense of who is truly in control of Recce Pharmaceuticals Ltd (ASX:RCE), it is important to understand the ownership structure of the business. We can see that retail investors own the lion's ...